Beneficial effects of water-based exercise in patients with chronic kidney disease

The arteriovenous fistula (AVF) is the preferred hemodialysis vascular access, but it is complicated by high failure rates and attendant morbidity. This study provides the first description of a murine AVF model that recapitulates two salient features of hemodialysis AVFs, namely, anastomosis of end-vein to side-artery to create the AVF and the presence of chronic kidney disease (CKD). CKD reduced AVF blood flow, observed as early as 3 days after AVF creation, and increased neointimal hyperplasia, venous wall thickness, thrombus formation, and vasculopathic gene expression in the AVF. These adverse effects of CKD could not be ascribed to preexisting alterations in blood pressure or vascular reactivity in this CKD model. In addition to vasculopathic genes, CKD induced potentially vasoprotective genes in the AVF such as heme oxygenase-1 (HO-1) and HO-2. To determine whether prior HO-1 upregulation may protect in this model, we upregulated HO-1 by adeno-associated viral gene delivery, achieving marked venous induction of the HO-1 protein and HO activity. Such HO-1 upregulation improved AVF blood flow and decreased venous wall thickness in the AVF. Finally, we demonstrate that the administration of carbon monoxide, a product of HO, acutely increased AVF blood flow. This study thus demonstrates: 1) the feasibility of a clinically relevant murine AVF model created in the presence of CKD and involving an end-vein to side-artery anastomosis; 2) the exacerbatory effect of CKD on clinically relevant features of this model; and 3) the beneficial effects in this model conferred by HO-1 upregulation by adeno-associated viral gene delivery.

Download Full-text

Beneficial Effects of 6-Month Supplementation with Omega-3 Acids on Selected Inflammatory Markers in Patients with Chronic Kidney Disease Stages 1–3

BioMed Research International ◽

10.1155/2017/1680985 ◽

2017 ◽

Vol 2017 ◽

pp. 1-7 ◽

Cited By ~ 3

Author(s):

Agnieszka Pluta ◽

Paweł Stróżecki ◽

Jacek Kęsy ◽

Kinga Lis ◽

Beata Sulikowska ◽

...

Keyword(s):

Chronic Kidney Disease ◽

Kidney Disease ◽

Serum Concentration ◽

Reference Group ◽

Omega 3 ◽

Alpha Linolenic Acid ◽

Beneficial Effects ◽

Markers Of Inflammation ◽

Wbc Count

Introduction. Chronic kidney disease (CKD) is accompanied by inflammation. The aim of this study was to evaluate the effect of 6-month supplementation with omega-3 acids on selected markers of inflammation in patients with CKD stages 1–3. Methods. Six-month supplementation with omega-3 acids (2 g/day) was administered to 87 CKD patients and to 27 healthy individuals. At baseline and after follow-up, blood was taken for C-reactive protein (CRP) and monocyte chemotactic protein-1 (MCP-1) concentration and white blood cell (WBC) count. Serum concentration of omega-3 acids—eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), and alpha-linolenic acid (ALA)—was determined using gas chromatography. And 24-hour urinary collection was performed to measure MCP-1 excretion. Results. After six-month omega-3 supplementation, ALA concentration increased in CKD patients and in the reference group, while EPA and DHA did not change. At follow-up, a significant decrease in urinary MCP-1 excretion in CKD (p=0.0012) and in the reference group (p=0.001) was found. CRP, serum MCP-1, and WBC did not change significantly. The estimated glomerular filtration rate (eGFR) did not change significantly in the CKD group. Conclusions. The reduction of urinary MCP-1 excretion in the absence of MCP-1 serum concentration may suggest a beneficial effect of omega-3 supplementation on tubular MCP-1 production. Trial Registration. This study was registered in ClinicalTrials.gov (identifier: NCT02147002).

Download Full-text

Vitamin D Receptor Activators and Clinical Outcomes in Chronic Kidney Disease

International Journal of Nephrology ◽

10.4061/2011/419524 ◽

2011 ◽

Vol 2011 ◽

pp. 1-13 ◽

Cited By ~ 12

Author(s):

Luciana Gravellone ◽

Maria Antonietta Rizzo ◽

Valentina Martina ◽

Nicoletta Mezzina ◽

Anna Regalia ◽

...

Keyword(s):

Chronic Kidney Disease ◽

Vitamin D ◽

Kidney Disease ◽

Vitamin D Receptor ◽

Mineral Metabolism ◽

Controlled Trial ◽

Protective Role ◽

Hemodialysis Patients ◽

Vitamin D Metabolites ◽

Beneficial Effects

Vitamin D deficiency appears to be an underestimated risk factor for cardiovascular disease in patients with chronic kidney disease. Evidence from both basic science and clinical studies supports the possible protective role of vitamin D beyond its effect on mineral metabolism. Toxicity of pharmacologic doses of active vitamin D metabolites, in particular calcitriol, is mainly due to the possibility of positive calcium and phosphorus balance. Therefore, vitamin D analogs have been developed, which suppress PTH secretion and synthesis with reduced calcemic and phosphatemic effects. Observational studies suggest that in hemodialysis patients the use of a vitamin D receptor (VDR) activator, such as calcitriol, doxercalciferol, paricalcitol, or alfacalcidol, is associated with a reduced mortality when compared with nonusers of any VDR activator. In this article the existing literature on the topic is reviewed, although a more robust answer to the question of whether or not VDR activators have beneficial effects in hemodialysis patients will hopefully come from a randomized controlled trial.

Download Full-text

Beneficial effects of Fu-Zheng-Qu-Zhuo oral liquid combined with standard integrated therapy in patients with chronic kidney disease (stage 3–4)

Medicine ◽

10.1097/md.0000000000007448 ◽

2017 ◽

Vol 96 (28) ◽

pp. e7448 ◽

Cited By ~ 2

Author(s):

Shen Li ◽

Xiang-Rong Rao ◽

Xi-Wen Dai ◽

Kun Pei ◽

Lee Wang ◽

...

Keyword(s):

Chronic Kidney Disease ◽

Kidney Disease ◽

Chronic Kidney Disease Stage ◽

Disease Stage ◽

Beneficial Effects ◽

Integrated Therapy ◽

Oral Liquid

Download Full-text

The potency of PLGA-Encapsulated Epigallocatechin Gallate (EGCG) as adjuvant therapy for chronic kidney disease

World Journal of Advanced Research and Reviews ◽

10.30574/wjarr.2022.13.1.0019 ◽

2022 ◽

Vol 13 (1) ◽

pp. 273-279

Author(s):

Deandra Maharani Widiatmaja ◽

Alyaa Ulaa Dhiya Ul Haq ◽

Dinda Dwi Purwati ◽

Arifa Mustika

Keyword(s):

Chronic Kidney Disease ◽

Kidney Disease ◽

Adjuvant Therapy ◽

Mitochondrial Function ◽

Kidney Diseases ◽

Epigallocatechin Gallate ◽

Pharmacokinetic Profile ◽

Protective Agent ◽

Beneficial Effects ◽

Plga Encapsulation

Chronic kidney disease (CKD) prevalence keeps increasing worldwide and being particular concern due to its morbidity and mortality. However, current CKD therapy are known to be economically costly and not necessarily provide better outcomes. Epigallocatechin gallate (EGCG) is one of the substances that widely studied as perspective therapeutic agents of CKD due to its anti-inflammatory, antioxidant, and enhancing mitochondrial function ability. However, the use of EGCG is limited to low bioavailability and poor pharmacokinetic profile. Encapsulation of EGCG with PLGA is expected to increase the efficacy of EGCG especially for its use as the kidney protective agent and optimize therapy of CKD. Thus, this study aims to analyze the potency of PLGA-encapsulated EGCG as the adjuvant therapy for CKD. This study was a narrative review summarizes studies related to current adjuvant therapy of CKD. EGCG has beneficial effects in reducing pro-inflammatory cytokines among chronic kidney disease. EGCG also can increase scavenging of free radicals to decrease reactive oxygen species. EGCG is known to enhance mitochondrial function and increase mitochondrial protection to prevent apoptosis in various kidney diseases. Combination of PLGA encapsulation with EGCG has a beneficial effect in improving the delivery, bioavailability, stability, and the pharmacokinetic profile of EGCG. PLGA-encapsulated EGCG also provides a better therapeutic effect on preventing and decreasing progression of kidney damage. Finally, this study concluded that combination of PLGA-encapsulated EGCG has a potency as the adjuvant therapy of CKD.

Download Full-text

Clinical Implication of the Renin-angiotensin-aldosterone Blockers in Chronic Kidney Disease Undergoing Hemodialysis

The Open Cardiovascular Medicine Journal ◽

10.2174/1874192401408010006 ◽

2014 ◽

Vol 8 (1) ◽

pp. 6-11 ◽

Cited By ~ 1

Author(s):

Yoshiyuki Morishita ◽

Eiji Kusano ◽

Daisuke Nagata

Keyword(s):

Cardiovascular Disease ◽

Chronic Kidney Disease ◽

Kidney Disease ◽

Clinical Implication ◽

Renin Angiotensin Aldosterone System ◽

Renin Angiotensin ◽

Beneficial Effects

The renin-angiotensin-aldosterone system (RAAS) blockers have been widely used in chronic kidney disease patients undergoing hemodialysis; however, whether RAAS blockers have beneficial effects for cardiovascular disease in those patients has not been fully defined. This review focuses on the effects of RAAS blockers in chronic kidney disease undergoing hemodialysis for cardiovascular disease.

Download Full-text

Very Low Protein Diet for Patients with Chronic Kidney Disease: Recent Insights

Journal of Clinical Medicine ◽

10.3390/jcm8050718 ◽

2019 ◽

Vol 8 (5) ◽

pp. 718 ◽

Cited By ~ 6

Author(s):

Lucia Di Micco ◽

Luca Di Lullo ◽

Antonio Bellasi ◽

Biagio R. Di Iorio

Keyword(s):

Chronic Kidney Disease ◽

Kidney Disease ◽

Nutritional Therapy ◽

Sodium Content ◽

Protein Diet ◽

Low Protein Diet ◽

Phosphate Binders ◽

Beneficial Effects ◽

Low Protein ◽

Very Low Protein Diet

Use of nutritional therapy (NT) in chronic kidney disease (CKD) patients is still debated among nephrologists, but it represents a fundamental point in the conservative treatment of CKD. It has been used for years and it has new goals today, such as (1) the reduction of edema, diuretics, and blood pressure values with a low sodium-content diet; (2) the dose reduction of phosphate levels and phosphate binders; (3) the administration of bicarbonate with vegetables in order to correct metabolic acidosis and delay CKD progression; (4) the reduction of the number and the doses of drugs and chemical substances; and (5) the lowering of urea levels, the cure of intestinal microbioma, and the reduction of cyanates levels (such as indoxyl-sulphate and p-cresol sulphate), which are the most recent known advantages achievable with NT. In conclusion, NT and especially very low protein diet (VLPD) have several beneficial effects in CKD patients and slows the progression of CKD.

Download Full-text

Inflammation and Oxidative Stress in Chronic Kidney Disease—Potential Therapeutic Role of Minerals, Vitamins and Plant-Derived Metabolites

International Journal of Molecular Sciences ◽

10.3390/ijms21010263 ◽

2019 ◽

Vol 21 (1) ◽

pp. 263 ◽

Cited By ~ 16

Author(s):

Shara Francesca Rapa ◽

Biagio Raffaele Di Iorio ◽

Pietro Campiglia ◽

August Heidland ◽

Stefania Marzocco

Keyword(s):

Oxidative Stress ◽

Chronic Kidney Disease ◽

Kidney Disease ◽

Antioxidant Properties ◽

Small Sample ◽

Beneficial Effects ◽

Antioxidant Agents ◽

Antioxidative Agents ◽

Anti Inflammatory ◽

And Oxidative Stress

Chronic kidney disease (CKD) is a debilitating pathology with various causal factors, culminating in end stage renal disease (ESRD) requiring dialysis or kidney transplantation. The progression of CKD is closely associated with systemic inflammation and oxidative stress, which are responsible for the manifestation of numerous complications such as malnutrition, atherosclerosis, coronary artery calcification, heart failure, anemia and mineral and bone disorders, as well as enhanced cardiovascular mortality. In addition to conventional therapy with anti-inflammatory and antioxidative agents, growing evidence has indicated that certain minerals, vitamins and plant-derived metabolites exhibit beneficial effects in these disturbances. In the current work, we review the anti-inflammatory and antioxidant properties of various agents which could be of potential benefit in CKD/ESRD. However, the related studies were limited due to small sample sizes and short-term follow-up in many trials. Therefore, studies of several anti-inflammatory and antioxidant agents with long-term follow-ups are necessary.

Download Full-text